Cargando…
Biomarkers in acute myocardial infarction: current perspectives
PURPOSE: Acute myocardial infarction (AMI) is the most common cause of death in the world. Comprehensive risk assessment of patients presenting with chest pain and eliminating undesirable results should decrease morbidity and mortality rates, increase the quality of life of patients, and decrease he...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340361/ https://www.ncbi.nlm.nih.gov/pubmed/30697054 http://dx.doi.org/10.2147/VHRM.S166157 |
_version_ | 1783388781622067200 |
---|---|
author | Aydin, Suleyman Ugur, Kader Aydin, Suna Sahin, İbrahim Yardim, Meltem |
author_facet | Aydin, Suleyman Ugur, Kader Aydin, Suna Sahin, İbrahim Yardim, Meltem |
author_sort | Aydin, Suleyman |
collection | PubMed |
description | PURPOSE: Acute myocardial infarction (AMI) is the most common cause of death in the world. Comprehensive risk assessment of patients presenting with chest pain and eliminating undesirable results should decrease morbidity and mortality rates, increase the quality of life of patients, and decrease health expenditure in many countries. In this study, the advantages and disadvantages of the enzymatic and nonenzymatic biomarkers used in the diagnosis of patients with AMI are given in historical sequence, and some candidate biomarkers – hFABP, GPBB, S100, PAPP-A, RP, TNF, IL6, IL18, CD40 ligand, MPO, MMP9, cell-adhesion molecules, oxidized LDL, glutathione, homocysteine, fibrinogen, and D-dimer procalcitonin – with a possible role in the diagnosis of AMI are discussed. METHODS: The present study was carried out using meta-analyses, reviews of clinical trials, evidence-based medicine, and guidelines indexed in PubMed and Web of Science. RESULTS: These numerous AMI biomarkers guide clinical applications (diagnostic methods, risk stratification, and treatment). Today, however, TnI remains the gold standard for the diagnosis of AMI. Details in the text will be given of many biomarkers for the diagnosis of AMI. CONCLUSION: We evaluated the advantages and disadvantages of routine enzymatic and nonenzymatic biomarkers and the literature evidence of other candidate biomarkers in the diagnosis of AMI, and discuss challenges and constraints that limit translational use from bench to bedside. |
format | Online Article Text |
id | pubmed-6340361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63403612019-01-29 Biomarkers in acute myocardial infarction: current perspectives Aydin, Suleyman Ugur, Kader Aydin, Suna Sahin, İbrahim Yardim, Meltem Vasc Health Risk Manag Review PURPOSE: Acute myocardial infarction (AMI) is the most common cause of death in the world. Comprehensive risk assessment of patients presenting with chest pain and eliminating undesirable results should decrease morbidity and mortality rates, increase the quality of life of patients, and decrease health expenditure in many countries. In this study, the advantages and disadvantages of the enzymatic and nonenzymatic biomarkers used in the diagnosis of patients with AMI are given in historical sequence, and some candidate biomarkers – hFABP, GPBB, S100, PAPP-A, RP, TNF, IL6, IL18, CD40 ligand, MPO, MMP9, cell-adhesion molecules, oxidized LDL, glutathione, homocysteine, fibrinogen, and D-dimer procalcitonin – with a possible role in the diagnosis of AMI are discussed. METHODS: The present study was carried out using meta-analyses, reviews of clinical trials, evidence-based medicine, and guidelines indexed in PubMed and Web of Science. RESULTS: These numerous AMI biomarkers guide clinical applications (diagnostic methods, risk stratification, and treatment). Today, however, TnI remains the gold standard for the diagnosis of AMI. Details in the text will be given of many biomarkers for the diagnosis of AMI. CONCLUSION: We evaluated the advantages and disadvantages of routine enzymatic and nonenzymatic biomarkers and the literature evidence of other candidate biomarkers in the diagnosis of AMI, and discuss challenges and constraints that limit translational use from bench to bedside. Dove Medical Press 2019-01-17 /pmc/articles/PMC6340361/ /pubmed/30697054 http://dx.doi.org/10.2147/VHRM.S166157 Text en © 2019 Aydin et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Aydin, Suleyman Ugur, Kader Aydin, Suna Sahin, İbrahim Yardim, Meltem Biomarkers in acute myocardial infarction: current perspectives |
title | Biomarkers in acute myocardial infarction: current perspectives |
title_full | Biomarkers in acute myocardial infarction: current perspectives |
title_fullStr | Biomarkers in acute myocardial infarction: current perspectives |
title_full_unstemmed | Biomarkers in acute myocardial infarction: current perspectives |
title_short | Biomarkers in acute myocardial infarction: current perspectives |
title_sort | biomarkers in acute myocardial infarction: current perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340361/ https://www.ncbi.nlm.nih.gov/pubmed/30697054 http://dx.doi.org/10.2147/VHRM.S166157 |
work_keys_str_mv | AT aydinsuleyman biomarkersinacutemyocardialinfarctioncurrentperspectives AT ugurkader biomarkersinacutemyocardialinfarctioncurrentperspectives AT aydinsuna biomarkersinacutemyocardialinfarctioncurrentperspectives AT sahinibrahim biomarkersinacutemyocardialinfarctioncurrentperspectives AT yardimmeltem biomarkersinacutemyocardialinfarctioncurrentperspectives |